Report cover image

Global Respiratory Syncytial Virus Vaccine for the Elderly Market by Size, by Type, by Application, by Region, History and Forecast 2020-2031

Publisher APO Research, Inc.
Published Jul 08, 2025
Length 196 Pages
SKU # APRC20277480

Description

Summary

According to APO Research, The global Respiratory Syncytial Virus Vaccine for the Elderly market is projected to grow from US$ million in 2025 to US$ million by 2031, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The US & Canada market for Respiratory Syncytial Virus Vaccine for the Elderly is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Asia-Pacific market for Respiratory Syncytial Virus Vaccine for the Elderly is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The China market for Respiratory Syncytial Virus Vaccine for the Elderly is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Europe market for Respiratory Syncytial Virus Vaccine for the Elderly is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The major global manufacturers of Respiratory Syncytial Virus Vaccine for the Elderly include GSK, Icosavax, Moderna, Pfizer, RNAimmune, Sanofi, Advaccine, Daiichi Sankyo and Immorna, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for Respiratory Syncytial Virus Vaccine for the Elderly, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2020-2024, estimates for 2025, and projections of CAGR through 2031.

This report researches the key producers of Respiratory Syncytial Virus Vaccine for the Elderly, also provides the sales of main regions and countries. Of the upcoming market potential for Respiratory Syncytial Virus Vaccine for the Elderly, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Respiratory Syncytial Virus Vaccine for the Elderly sales, revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global Respiratory Syncytial Virus Vaccine for the Elderly market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2020 to 2031. Evaluation and forecast the market size for Respiratory Syncytial Virus Vaccine for the Elderly sales, projected growth trends, production technology, application and end-user industry.


Respiratory Syncytial Virus Vaccine for the Elderly Segment by Company


GSK
Icosavax
Moderna
Pfizer
RNAimmune
Sanofi
Advaccine
Daiichi Sankyo
Immorna
Blue Lake Biotechnology
Clover Biopharma
Innorna
Starna Therapeutics

Respiratory Syncytial Virus Vaccine for the Elderly Segment by Type


Recombinant Protein Vaccine
Nucleic Acid Vaccines
Others

Respiratory Syncytial Virus Vaccine for the Elderly Segment by Application


Hospital
Centers for Disease Control and Prevention
Others

Respiratory Syncytial Virus Vaccine for the Elderly Segment by Region


North America

United States
Canada
Mexico
Europe

Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific

China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America

Brazil
Argentina
Chile
Middle East & Africa

Egypt
South Africa
Israel
Türkiye
GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Respiratory Syncytial Virus Vaccine for the Elderly market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Respiratory Syncytial Virus Vaccine for the Elderly and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Respiratory Syncytial Virus Vaccine for the Elderly.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Respiratory Syncytial Virus Vaccine for the Elderly market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2020-2031).
Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Respiratory Syncytial Virus Vaccine for the Elderly manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Respiratory Syncytial Virus Vaccine for the Elderly in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Revenue of Respiratory Syncytial Virus Vaccine for the Elderly in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights of the report

Please Note: Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.

Table of Contents

196 Pages
1 Market Overview
1.1 Product Definition
1.2 Global Respiratory Syncytial Virus Vaccine for the Elderly Market Size, 2020 VS 2024 VS 2031
1.3 Global Respiratory Syncytial Virus Vaccine for the Elderly Market Size Estimates and Forecasts (2020-2031)
1.4 Global Respiratory Syncytial Virus Vaccine for the Elderly Sales Estimates and Forecasts (2020-2031)
1.5 Global Respiratory Syncytial Virus Vaccine for the Elderly Market Average Price (2020-2031)
1.6 Assumptions and Limitations
1.7 Study Goals and Objectives
2 Global Respiratory Syncytial Virus Vaccine for the Elderly Market Dynamics
2.1 Respiratory Syncytial Virus Vaccine for the Elderly Industry Trends
2.2 Respiratory Syncytial Virus Vaccine for the Elderly Industry Drivers
2.3 Respiratory Syncytial Virus Vaccine for the Elderly Industry Opportunities and Challenges
2.4 Respiratory Syncytial Virus Vaccine for the Elderly Industry Restraints
3 Respiratory Syncytial Virus Vaccine for the Elderly Market by Manufacturers
3.1 Global Respiratory Syncytial Virus Vaccine for the Elderly Revenue by Manufacturers (2020-2025)
3.2 Global Respiratory Syncytial Virus Vaccine for the Elderly Sales by Manufacturers (2020-2025)
3.3 Global Respiratory Syncytial Virus Vaccine for the Elderly Average Sales Price by Manufacturers (2020-2025)
3.4 Global Respiratory Syncytial Virus Vaccine for the Elderly Industry Manufacturers Ranking, 2023 VS 2024 VS 2025
3.5 Global Respiratory Syncytial Virus Vaccine for the Elderly Key Manufacturers Manufacturing Sites & Headquarters
3.6 Global Respiratory Syncytial Virus Vaccine for the Elderly Manufacturers, Product Type & Application
3.7 Global Respiratory Syncytial Virus Vaccine for the Elderly Manufacturers Establishment Date
3.8 Market Competitive Analysis
3.8.1 Global Respiratory Syncytial Virus Vaccine for the Elderly Market CR5 and HHI
3.8.2 Global Top 5 and 10 Respiratory Syncytial Virus Vaccine for the Elderly Players Market Share by Revenue in 2024
3.8.3 2024 Respiratory Syncytial Virus Vaccine for the Elderly Tier 1, Tier 2, and Tier 3
4 Respiratory Syncytial Virus Vaccine for the Elderly Market by Type
4.1 Respiratory Syncytial Virus Vaccine for the Elderly Type Introduction
4.1.1 Recombinant Protein Vaccine
4.1.2 Nucleic Acid Vaccines
4.1.3 Others
4.2 Global Respiratory Syncytial Virus Vaccine for the Elderly Sales by Type
4.2.1 Global Respiratory Syncytial Virus Vaccine for the Elderly Sales by Type (2020 VS 2024 VS 2031)
4.2.2 Global Respiratory Syncytial Virus Vaccine for the Elderly Sales by Type (2020-2031)
4.2.3 Global Respiratory Syncytial Virus Vaccine for the Elderly Sales Market Share by Type (2020-2031)
4.3 Global Respiratory Syncytial Virus Vaccine for the Elderly Revenue by Type
4.3.1 Global Respiratory Syncytial Virus Vaccine for the Elderly Revenue by Type (2020 VS 2024 VS 2031)
4.3.2 Global Respiratory Syncytial Virus Vaccine for the Elderly Revenue by Type (2020-2031)
4.3.3 Global Respiratory Syncytial Virus Vaccine for the Elderly Revenue Market Share by Type (2020-2031)
5 Respiratory Syncytial Virus Vaccine for the Elderly Market by Application
5.1 Respiratory Syncytial Virus Vaccine for the Elderly Application Introduction
5.1.1 Hospital
5.1.2 Centers for Disease Control and Prevention
5.1.3 Others
5.2 Global Respiratory Syncytial Virus Vaccine for the Elderly Sales by Application
5.2.1 Global Respiratory Syncytial Virus Vaccine for the Elderly Sales by Application (2020 VS 2024 VS 2031)
5.2.2 Global Respiratory Syncytial Virus Vaccine for the Elderly Sales by Application (2020-2031)
5.2.3 Global Respiratory Syncytial Virus Vaccine for the Elderly Sales Market Share by Application (2020-2031)
5.3 Global Respiratory Syncytial Virus Vaccine for the Elderly Revenue by Application
5.3.1 Global Respiratory Syncytial Virus Vaccine for the Elderly Revenue by Application (2020 VS 2024 VS 2031)
5.3.2 Global Respiratory Syncytial Virus Vaccine for the Elderly Revenue by Application (2020-2031)
5.3.3 Global Respiratory Syncytial Virus Vaccine for the Elderly Revenue Market Share by Application (2020-2031)
6 Global Respiratory Syncytial Virus Vaccine for the Elderly Sales by Region
6.1 Global Respiratory Syncytial Virus Vaccine for the Elderly Sales by Region: 2020 VS 2024 VS 2031
6.2 Global Respiratory Syncytial Virus Vaccine for the Elderly Sales by Region (2020-2031)
6.2.1 Global Respiratory Syncytial Virus Vaccine for the Elderly Sales by Region (2020-2025)
6.2.2 Global Respiratory Syncytial Virus Vaccine for the Elderly Sales Forecasted by Region (2025-2030)
6.3 North America
6.3.1 North America Respiratory Syncytial Virus Vaccine for the Elderly Sales Growth Rate by Country: 2020 VS 2024 VS 2031
6.3.2 North America Respiratory Syncytial Virus Vaccine for the Elderly Sales by Country (2020-2031)
6.3.3 U.S.
6.3.4 Canada
6.3.5 Mexico
6.4 Europe
6.4.1 Europe Respiratory Syncytial Virus Vaccine for the Elderly Sales Growth Rate by Country: 2020 VS 2024 VS 2031
6.4.2 Europe Respiratory Syncytial Virus Vaccine for the Elderly Sales by Country (2020-2031)
6.4.3 Germany
6.4.4 France
6.4.5 U.K.
6.4.6 Italy
6.4.7 Netherlands
6.5 Asia Pacific
6.5.1 Asia Pacific Respiratory Syncytial Virus Vaccine for the Elderly Sales Growth Rate by Country: 2020 VS 2024 VS 2031
6.5.2 Asia Pacific Respiratory Syncytial Virus Vaccine for the Elderly Sales by Country (2020-2031)
6.5.3 China
6.5.4 Japan
6.5.5 South Korea
6.5.6 Southeast Asia
6.5.7 India
6.5.8 Australia
6.6 South America, Middle East and Africa
6.6.1 South America, Middle East and Africa Respiratory Syncytial Virus Vaccine for the Elderly Sales Growth Rate by Country: 2020 VS 2024 VS 2031
6.6.2 South America, Middle East and Africa Respiratory Syncytial Virus Vaccine for the Elderly Sales by Country (2020-2031)
6.6.3 Brazil
6.6.4 South Africa
6.6.5 Saudi Arabia
6.6.6 Turkey
6.6.6 Argentina
6.6.6 UAE
6.6.6 Egypt
6.6.6 Chile
7 Global Respiratory Syncytial Virus Vaccine for the Elderly Revenue by Region
7.1 Global Respiratory Syncytial Virus Vaccine for the Elderly Revenue by Region
7.1.1 Global Respiratory Syncytial Virus Vaccine for the Elderly Revenue by Region: 2020 VS 2024 VS 2031
7.1.2 Global Respiratory Syncytial Virus Vaccine for the Elderly Revenue by Region (2020-2025)
7.1.3 Global Respiratory Syncytial Virus Vaccine for the Elderly Revenue by Region (2026-2031)
7.1.4 Global Respiratory Syncytial Virus Vaccine for the Elderly Revenue Market Share by Region (2020-2031)
7.2 North America
7.2.1 North America Respiratory Syncytial Virus Vaccine for the Elderly Revenue (2020-2031)
7.2.2 North America Respiratory Syncytial Virus Vaccine for the Elderly Revenue Share by Country: 2020 VS 2024 VS 2031
7.3 Europe
7.3.1 Europe Respiratory Syncytial Virus Vaccine for the Elderly Revenue (2020-2031)
7.3.2 Europe Respiratory Syncytial Virus Vaccine for the Elderly Revenue Share by Country: 2020 VS 2024 VS 2031
7.4 Asia-Pacific
7.4.1 Asia-Pacific Respiratory Syncytial Virus Vaccine for the Elderly Revenue (2020-2031)
7.4.2 Asia-Pacific Respiratory Syncytial Virus Vaccine for the Elderly Revenue Share by Country: 2020 VS 2024 VS 2031
7.5 South America, Middle East and Africa
7.5.1 South America, Middle East and Africa Respiratory Syncytial Virus Vaccine for the Elderly Revenue (2020-2031)
7.5.2 South America, Middle East and Africa Respiratory Syncytial Virus Vaccine for the Elderly Revenue Share by Country: 2020 VS 2024 VS 2031
8 Company Profiles
8.1 GSK
8.1.1 GSK Comapny Information
8.1.2 GSK Business Overview
8.1.3 GSK Respiratory Syncytial Virus Vaccine for the Elderly Sales, Price, Revenue and Gross Margin (2020-2025)
8.1.4 GSK Respiratory Syncytial Virus Vaccine for the Elderly Product Portfolio
8.1.5 GSK Recent Developments
8.2 Icosavax
8.2.1 Icosavax Comapny Information
8.2.2 Icosavax Business Overview
8.2.3 Icosavax Respiratory Syncytial Virus Vaccine for the Elderly Sales, Price, Revenue and Gross Margin (2020-2025)
8.2.4 Icosavax Respiratory Syncytial Virus Vaccine for the Elderly Product Portfolio
8.2.5 Icosavax Recent Developments
8.3 Moderna
8.3.1 Moderna Comapny Information
8.3.2 Moderna Business Overview
8.3.3 Moderna Respiratory Syncytial Virus Vaccine for the Elderly Sales, Price, Revenue and Gross Margin (2020-2025)
8.3.4 Moderna Respiratory Syncytial Virus Vaccine for the Elderly Product Portfolio
8.3.5 Moderna Recent Developments
8.4 Pfizer
8.4.1 Pfizer Comapny Information
8.4.2 Pfizer Business Overview
8.4.3 Pfizer Respiratory Syncytial Virus Vaccine for the Elderly Sales, Price, Revenue and Gross Margin (2020-2025)
8.4.4 Pfizer Respiratory Syncytial Virus Vaccine for the Elderly Product Portfolio
8.4.5 Pfizer Recent Developments
8.5 RNAimmune
8.5.1 RNAimmune Comapny Information
8.5.2 RNAimmune Business Overview
8.5.3 RNAimmune Respiratory Syncytial Virus Vaccine for the Elderly Sales, Price, Revenue and Gross Margin (2020-2025)
8.5.4 RNAimmune Respiratory Syncytial Virus Vaccine for the Elderly Product Portfolio
8.5.5 RNAimmune Recent Developments
8.6 Sanofi
8.6.1 Sanofi Comapny Information
8.6.2 Sanofi Business Overview
8.6.3 Sanofi Respiratory Syncytial Virus Vaccine for the Elderly Sales, Price, Revenue and Gross Margin (2020-2025)
8.6.4 Sanofi Respiratory Syncytial Virus Vaccine for the Elderly Product Portfolio
8.6.5 Sanofi Recent Developments
8.7 Advaccine
8.7.1 Advaccine Comapny Information
8.7.2 Advaccine Business Overview
8.7.3 Advaccine Respiratory Syncytial Virus Vaccine for the Elderly Sales, Price, Revenue and Gross Margin (2020-2025)
8.7.4 Advaccine Respiratory Syncytial Virus Vaccine for the Elderly Product Portfolio
8.7.5 Advaccine Recent Developments
8.8 Daiichi Sankyo
8.8.1 Daiichi Sankyo Comapny Information
8.8.2 Daiichi Sankyo Business Overview
8.8.3 Daiichi Sankyo Respiratory Syncytial Virus Vaccine for the Elderly Sales, Price, Revenue and Gross Margin (2020-2025)
8.8.4 Daiichi Sankyo Respiratory Syncytial Virus Vaccine for the Elderly Product Portfolio
8.8.5 Daiichi Sankyo Recent Developments
8.9 Immorna
8.9.1 Immorna Comapny Information
8.9.2 Immorna Business Overview
8.9.3 Immorna Respiratory Syncytial Virus Vaccine for the Elderly Sales, Price, Revenue and Gross Margin (2020-2025)
8.9.4 Immorna Respiratory Syncytial Virus Vaccine for the Elderly Product Portfolio
8.9.5 Immorna Recent Developments
8.10 Blue Lake Biotechnology
8.10.1 Blue Lake Biotechnology Comapny Information
8.10.2 Blue Lake Biotechnology Business Overview
8.10.3 Blue Lake Biotechnology Respiratory Syncytial Virus Vaccine for the Elderly Sales, Price, Revenue and Gross Margin (2020-2025)
8.10.4 Blue Lake Biotechnology Respiratory Syncytial Virus Vaccine for the Elderly Product Portfolio
8.10.5 Blue Lake Biotechnology Recent Developments
8.11 Clover Biopharma
8.11.1 Clover Biopharma Comapny Information
8.11.2 Clover Biopharma Business Overview
8.11.3 Clover Biopharma Respiratory Syncytial Virus Vaccine for the Elderly Sales, Price, Revenue and Gross Margin (2020-2025)
8.11.4 Clover Biopharma Respiratory Syncytial Virus Vaccine for the Elderly Product Portfolio
8.11.5 Clover Biopharma Recent Developments
8.12 Innorna
8.12.1 Innorna Comapny Information
8.12.2 Innorna Business Overview
8.12.3 Innorna Respiratory Syncytial Virus Vaccine for the Elderly Sales, Price, Revenue and Gross Margin (2020-2025)
8.12.4 Innorna Respiratory Syncytial Virus Vaccine for the Elderly Product Portfolio
8.12.5 Innorna Recent Developments
8.13 Starna Therapeutics
8.13.1 Starna Therapeutics Comapny Information
8.13.2 Starna Therapeutics Business Overview
8.13.3 Starna Therapeutics Respiratory Syncytial Virus Vaccine for the Elderly Sales, Price, Revenue and Gross Margin (2020-2025)
8.13.4 Starna Therapeutics Respiratory Syncytial Virus Vaccine for the Elderly Product Portfolio
8.13.5 Starna Therapeutics Recent Developments
9 Value Chain and Sales Channels Analysis
9.1 Respiratory Syncytial Virus Vaccine for the Elderly Value Chain Analysis
9.1.1 Respiratory Syncytial Virus Vaccine for the Elderly Key Raw Materials
9.1.2 Raw Materials Key Suppliers
9.1.3 Manufacturing Cost Structure
9.1.4 Respiratory Syncytial Virus Vaccine for the Elderly Production Mode & Process
9.2 Respiratory Syncytial Virus Vaccine for the Elderly Sales Channels Analysis
9.2.1 Direct Comparison with Distribution Share
9.2.2 Respiratory Syncytial Virus Vaccine for the Elderly Distributors
9.2.3 Respiratory Syncytial Virus Vaccine for the Elderly Customers
10 Concluding Insights
11 Appendix
11.1 Reasons for Doing This Study
11.2 Research Methodology
11.3 Research Process
11.4 Authors List of This Report
11.5 Data Source
11.5.1 Secondary Sources
11.5.2 Primary Sources
11.6 Disclaimer
How Do Licenses Work?
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.